In a Level-1 study,
- DUROLANE was proven to be noninferior to steroid at 6 weeks.†
- results favored DUROLANE for reduction in WOMAC pain, function and stiffness scores from weeks 12 to 26.
- a significant reduction from baseline to week 26 in WOMAC pain scores was achieved with DUROLANE vs steroid.
Effect-sizes for WOMAC domains with 95% CIs during the blinded phase of the study.
†The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.